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Abstract  
Background: Lassa fever is a viral hemorrhagic fever that is endo-epidemic in Edo state, with case 
fatality of 90-100% if not treated. It has been claimed that early treatment with Ribavirin reduces 
mortality to less than 20%. This study was carried out to assert/confirm or refute/reject this claim. 
Aim: To review the clinical features, laboratory findings of Lassa fever and the outcome of confirmed 
cases treated with Ribavirin. 
Methodology: The study was a case series study of the first 41 cases that were treated with Ribavirin in 
the Lassa fever isolation ward from 28
th
 November 2010 to 26
th
 May 2011. 
Results: Up to 63.4% of cases presented late (onset of illness greater than 6 days at presentation). 
Fever remains the predominant presenting feature of the disease (97.5%). Of the cases that were 
admitted, 41 were treated, 31 recovered and 9 died, giving a case-fatality rate of 22%. One discharged 
against medical advice.  
Conclusion: Lassa fever victims still present late at the hospital and fever remains the predominant 
presenting feature. Early Ribavirin treatment improves treatment outcome of Lassa fever in confirmed 
cases. 
Recommendations: The Federal, States and Local government area council members must make 
efforts to create public awareness on early presentation, diagnosis and prompt treatment with 
Ribavirin. 
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1. Introduction 
Lassa fever is an acute viral hemorrhagic fever (Frame et al., 1970). It is Endo-endemic in most states 
in Nigeria (Akpede et al., 2009; Ehichioya et al., 2012) with Edo state accounting for a high number of 
cases (Reliefweb, 2016). It is the cause in 1.6% of all children admissions at the apex health institute in 
Edo central senatorial district (Akpede et al., 2009). The early symptoms of the disease are similar to 
those found in other common febrile illnesses in our environment (McCormick et al., 1987; Richmond 
et al., 2003; Month et al., 1975), which poses serious challenges to the early diagnosis and treatment of 
Lassa fever cases and resulting in case fatalities of 50-90% (Richmond et al., 2003). Ribavirin is the 
drug of choice for the treatment of Lassa Fever (LF). It is a nucleoside analogue which is more 
effective when given within the first 6 days of onset of illness (McCormick et al., 1986).
 
The 
recommended case definition for Lassa fever in the current National Technical Guidelines for 
Integrated Disease Surveillance and Response is not sensitive in detecting the disease at the early stage. 
According to the guidelines, a suspected case of the disease is any person with an acute onset of fever 
who does not respond to treatment for the usual causes of fever in the area, with at least one of the 
following signs: bloody diarrhea, bleeding from the gums, bleeding into skin, eyes and urine (FMOH, 
2009).
 
This results in many false negatives in the early phase because in most cases, bleeding does not 
occur in the early stages of the disease (Akpede et al., 2009).
 
This makes an appraisal of the current 
IDSR and the development of an appropriate case definition with higher degree of certainty necessary 
in order to reduce the public health impact of the disease. This study attempts to identify and describe 
clinical features and laboratory findings in early stage of LF in order to arrive at an accurate case 
definition for Lassa fever. The study will also confirm or reject the claim that Ribavirin improves 
outcome. There is limited country capacity with respect to laboratory diagnosis of Lassa fever. There 
are only three reference laboratories for the diagnosis of LF. Thus, an improved case definition is 
needed for quick action. 
 
2. Method 
2.1 Study Area  
The study was carried out at the Institute of Lassa Fever Research and Control (ILFRC), Irrua 
Specialist Teaching Hospital (ISTH), Irrua, in Esan Central area of Edo State, Nigeria. It is the foremost 
institute for the diagnosis, treatment and control of Lassa fever, which is endemic in the area. It is 
located at Kilometer 87, on the Benin-Auchi Express way and lies on latitude 06
048’ north and 
longitude 06
014’ east of the equator. It is bounded by Etsako West LGA in the north, Esan West LGA in 
the west, Esan North-East and Esan-South East LGAs in the east and Igueben LGA in the south. The 
Institute became operational in 2008 and has the following units: BSL3 diagnostic laboratory, a case 
management unit that provide curative services in a dedicated isolation ward, outreach (contact tracing 
and health education) including psycho-social care. The training and research unit provide technical 
support to staff offering direct health care services by organizing periodic training programmes. It 
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collaborates with other sectors by making the necessary linkages. The institute is supported by both 
international and local bodies, including the Bernhard-Nocht Institute for Tropical Medicine Germany, 
Harvard University, Public Health England, Federal Ministry of Health and other International agencies 
like the WHO. 
2.2 Study Design 
Descriptive cross sectional study. 
2.3 Study Population 
All RT-PCR confirmed cases of LF (41) admitted into the LF isolation ward. 
2.4 Study Period 
November 2010 to May 2011.  
2.5 Data Collection Method 
Patients’ medical records from the time of admission to discharge were examined to obtain information 
on socio-demographics, clinical features, hematological findings and treatment. 
2.6 Measurement of Variables 
Variables were measured as nominal and numerical variables.  
2.7 Data Analysis 
Data were entered and analysed using the Epi Info version 3.5.  
2.8 Ethical Approval  
Obtained from the Ethics and Research Committee; ISTH. Confidentiality was maintained as names 
were not recorded during data collection.  
 
3. Results 
 
Table 1. Sociodemographic Characteristics of Patients 
Characteristics Frequency (n=41) Percent 
Age (years) 
≤10 
11-20 
21-30 
31-40 
41-50 
51-60 
≥61 
 
1 
3 
15 
6 
6 
6 
4 
 
2.4 
7.2 
36.6 
14.6 
14.6 
14.6 
10.0 
Sex 
Male 
Female 
 
15 
26 
 
36.6 
63.3 
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Education 
None 
Primary 
Secondary 
Tertiary 
 
1 
1 
22 
17 
 
2.4 
2.4 
53.7 
41.5 
Religion 
Muslim 
Christian 
Others 
 
4 
30 
7 
 
9.8 
73.1 
17.1 
Travel History (Last One Month) 
Yes 
No 
 
6 
35 
 
14.6 
85.4 
Duration of illness at presentation (in days) 
3-6 
7-10 
>10 
 
15 
14 
12 
 
36.6 
34.1 
29.3 
Duration of admission 
6-10 days 
11-15 days 
>15days 
 
22 
10 
9 
 
53.7 
24.3 
22.0 
 
Table 2. Clinical Features of Patients with Lassa Fever 
Symptoms/signs* Frequency (n=41) Percent 
Early 
Abdominal pain 
Diarrhea 
Fainting 
Fever 
Headache 
Muscle pain 
Retrosternal pain 
Sore throat  
 
18 
12 
4 
40 
19 
6 
13 
15 
 
43.9  
29.3 
9.7 
97.5 
46.3 
14.6 
31.7 
36.6 
Late  
Altered sensorium 
Bleeding 
Cough 
 
9 
12 
31 
 
22.0  
29.2  
75.6  
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Dyspnoea 
Jaundice 
Irrational talk 
Seizures 
Vomiting 
Weakness 
5 
2 
3 
5 
24 
28 
12.2  
4.8 
7.3 
16.1 
58.5 
68.3 
Systolic BP (mm Hg) day 1 
≤90 
91-119 
120-139 
≥140 
BP not taken 
 
6 
9 
13 
4 
9 
 
14.6 
22.0 
31.7 
9.7 
22.0  
Systolic BP (mm Hg) day 2  
≤90 
91-119 
120-139 
≥140 
BP not taken 
 
5 
8 
12 
4 
12 
 
12.1 
19.5 
29.4 
9.7 
29.3 
Systolic BP (mm Hg) day 3  
≤90 
91-119 
120-139 
≥140 
BP not taken 
 
5 
9 
12 
4 
11 
 
12.1 
22.0 
29.4 
9.7 
26.8  
Diastolic BP (mm Hg) day 1  
≤60 
61-79 
80-89 
≥90 
BP not taken 
 
4 
21 
4 
3 
9 
 
9.7 
51.3 
9.7 
7.4 
21.9 
Diastolic BP (mm Hg) day 2  
≤60 
61-79 
80-89 
≥90 
BP not taken 
 
4 
14 
3 
8 
12 
 
9.7 
34.2 
7.4 
19.5 
29.2 
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Diastolic BP (mm Hg) day 3  
 ≤60 
61-79 
80-89 
≥90 
BP not taken 
 
2 
14 
10 
4 
11 
 
4.9 
34.1 
24.4 
9.7 
26.9  
* Multiple responses. 
 
Table 3. Laboratory Results of Patients with Lassa Fever (n=21) 
Investigation    Mean±2SD   Normal value 
FBC/ESR 
PCV  
WBC 
Lymphocytes 
Neutrophils 
Monocytes 
ESR 
Platelets  
 
36.31±25.0% 
8.6×10
9
±1.6.0×10
9
/L 
3.9×10
9
±2.8×10
9
/L 
6.0×10
9
±2.0×10
9
/L 
0.8×10
9
±0.2×10
9
/L 
56±26mm/hr 
251±208×10
9
/L 
 
F=36-47%, M=40-54% 
4.0-11.0×10
9
/L 
1.5-4.0×10
9
/L 
2.0-7.5×10
9
/L 
0.2-0.8×10
9
/L 
2-8mm/hr 
150-450×10
9
/L 
E&U&CR 
Sodium 
Potassium 
Urea 
Creatinine 
 
135.4±12.2mmol/L 
4.3±2.2mmol/L 
5.7±12.6mmol/L 
71.4±142.4µmol/L 
 
135-145mmol/L 
4.5-5.3mmol/L 
2.5-6.6mmol/L 
60-120µmol/L 
RBS 
RBS (day 1) 
RBS (day 2) 
RBS (day 3) 
 
142±109mg/dl 
175±123mg/dl 
212±166mg/dl 
 
LFT 
ALT 
AST 
ALP 
Total protein 
Albumin 
Globulin 
Total bilirubin 
Conjugated bilirubin 
 
80.83±86.9U/L 
168±176.2U/L 
78.3±58.5U/L 
7.3±3.2g/dl 
2.9±0.9g/dl 
6.6±2.5g/dl 
3.49±5.5mg/dl 
2.52±4.1mg/dl 
 
10-50U/L 
10-45U/L 
40-125U/L 
6-8g/dl 
3.5-5.0g/dl 
2-3.5g/dl 
0.2-1.2mg/dl 
0.1-0.4mg/dl 
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Table 4. Patients Treated with Ribavirin and Outcome 
Outcome Frequency (n=41) Percent 
Survived 
Died 
 DAMA 
31 
9 
1 
75.6 
22.0 
 2.4 
 
Table 5. Duration of Illness at Presentation and Case Fatality Rate (CFR) 
Duration of illness at presentation (in days) Frequency Deaths 
3-6 14 0 
7-10 14 3 
>10 12 6 
 
 
Figure 1. Lassa Fever Cases in Edo State, November 2010-May 2011 
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Figure 2. Lassa Fever Cases in Nigeria, November 2010-May 2011 
 
4. Discussion 
Clinical features and laboratory findings were similar to those described in available literature 
(Richmond et al., 2003; Month et al., 1975). About half of the patients were young adults aged between 
21 to 40 years. This is important since this age group is also the provider group in the Nigerian society 
(Odimegwu et al., 2008). Thus, adverse socioeconomic consequences can be anticipated from Lassa 
fever outbreaks and the death of breadwinners.  
Most of the patients were women. An overwhelming proportion of patients had at least secondary 
education. This is of importance because the Lassa fever virus vector—the multimammate rat—thrives 
in unhygienic peri-domestic conditions. In our society, women are the homemakers. There may be a 
public health benefit from educating women’s groups and associations about the mode of transmission 
of Lassa fever and how to prevent infection. 
Common early symptoms were fever, headache, abdominal pain and sore throat. The most common 
late symptom was cough. Vomiting and weakness were also frequent. These symptoms are non-specific, 
and are also seen in other common diseases such as malaria and typhoid fever. Laboratory diagnosis 
remains the gold standard, and in since the geographical area affected during Lassa fever outbreaks is 
so expansive, more laboratories may need to be built, equipped and appropriately staffed to facilitate 
early diagnosis and treatment. 
It is evident from this study that one of the factors which drive high case fatality is late presentation. 
The reasons for this may include long distance to hospitals and transportation constraints, being 
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admitted in private hospitals without appropriate diagnosis and referral, and fear of presenting to a 
teaching hospital. 
Many patients dread presenting to teaching hospitals, as they frequently have the perception that cases 
that get to teaching hospitals are irremediable. Therefore, many patients visit private hospitals or 
primary health centers that usually have no diagnostic facilities for Lassa fever. Indeed, it may be that 
the incidence and case fatality rates for Lassa fever are grossly underestimated. There may be a need to 
recommend Lassa fever screening as part of private hospitals’ routine investigations for febrile patients 
in endemic areas during epidemics. 
This study showed greater benefit from the administration of Ribavirin in the early stages of the disease, 
confirming a previous report that most patients who receive Ribavirin treatment early in the course of 
illness survive (McCorrnick et al., 1986). No deaths occurred in those who presented within 6 days of 
the onset of illness and most deaths occurred in patients who presented more than 10 days after the 
onset of illness.  
One patient got discharged against medical advice. There may be need for more health education 
outreaches and perhaps legal measures to enforce treatment for epidemic-prone diseases. 
 
5. Conclusion/Recommendations 
Thus, early Ribavirin treatment improves treatment outcome of Lassa fever. However early diagnosis 
still poses a problem, even in teaching hospitals. 
In ISTH, the case definition for LF is as follows: 
 Patient with 38°C fever for at least 2 days, 
 Excluded typhoid fever and malaria negative or just 1+ in thick smear, 
 Some or one of the following symptoms: chest pain, sore throat, headache, muscle pain, vomiting, 
and diarrhea. 
 Or: patients with fever who show bleeding or facial edema.  
 Or: patients with fever who do not respond to anti-malarials or antibiotics after 2 days of 
treatment. 
 Or: patients with fever who had contact with a confirmed Lassa fever case within the last three 
weeks. 
Clearly, this case definition is limited and many patients may be erroneously diagnosed with Lassa 
fever. Lassa fever cases that do not present with common findings may also be missed. This is of 
critical importance in far-flung rural areas where time to appropriate clinical/laboratory referral is of 
the essence. Further studies are needed in order to arrive at a better case definition for LF.  
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